Medical Developments International (MDI)
Neha Charya is a Senior Medical Affairs Associate at Medical Developments International (MDI), a position held since April 2022. Prior to this role, Neha served as PV-MI Lead at Ipsen from August 2020 to March 2022 and worked at MDI as a Medical Affairs Associate - PV from February 2019 to July 2020. Neha's earlier experience includes positions at Roche as a Drug Safety Associate and at Celgene as a Drug Safety Specialist. Additionally, Neha held multiple roles at Sciformix, including Training Lead in Pharmacovigilance and Team Lead in Drug Safety, following a training experience with Accutest Research Laboratories. Neha's educational background includes an MSc in Clinical Research and Pharmacovigilance from Cranfield University and a PGDPM in Pharmaceutical Management from the Institute of Clinical Research in India, along with a BSc in Biotechnology from Mithibai College of Arts, Chauhan Institute of Science and A.J. College of Commerce and Economics.
Medical Developments International (MDI)
"Delivering emergency medical solutions dedicated to improving patient outcomes" Medical Developments International (MDI) is one of Australia’s leading specialised healthcare companies. With an industry leading range of products in the areas of pain management, asthma and resuscitation, plus veterinary equipment, MDI has supplied healthcare professionals and patients innovative solutions since 1971. MDI is a publicly listed company on the Australian Stock Exchange (ASX) with both its head office and state of the art manufacturing facilities located in Victoria, Australia. MDI manufacture the innovative pain relief product, Penthrox® that has been widely adopted by organisations throughout Australia. MDI has a proud history in human and veterinary medicine, throughout Australia as well as internationally. For over 30 years MDI's key products have helped healthcare professionals achieve better health outcomes for their patients MDI is compliant with Good Manufacturing Practices as well as ISO 13485 for the manufacture of several of its products (including both pharmaceutical and medical products). Several MDI products are also CE marked, enabling them to be sold into the European Community.